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ABSTRACT
Antisense oligodeoxynucleotides (AS ODNs) are short single-stranded pieces of DNA that
are designed to hybridize with messenger RNA and thus offer a powerful technique for
controlling gene expression. Phosphorothioate AS ODNs are a well-established modification of
the traditional phosphodiester structure that increase the in vitro half-life of AS ODN activity. In
this work, we describe a method for controlling the hybridization activity of PS ODNs in cell
culture with a photo-reversible mechanism. The influence of a photocaging compound, 1-(4,5dimethoxy-2-nitrophenyl)diazoethane (DMNPE) on hybridization of ISIS 2302, a 20-mer PS
ODN, was modeled using a molecular beacon assay.

Based on this model, a relationship

between the number of attached cage groups and the inactivation of hybridization activity was
established. In addition, the light-dose effects on cell morphology and intracellular adhesion
molecule-1 (ICAM-1) target protein expression levels were used to determine that 40 J/cm2 of
UVA light was the maximum dose that could be used for photorestoration of antisense activity in
cell based studies. Active and DMNPE-inactivated forms of ISIS 2302 were delivered to human
epithelial carcinoma (HeLa) cells. 78 ± 2.9% of cells exposed to active ISIS 2302 showed
decreases in cytokine-stimulated ICAM-1 protein expression as measured by flow cytometry.
However, only 25 ± 1% of cells exposed to DMNPE-inactivated ISIS 2302 experienced
antisense effects. Subsequent exposure of HeLa cells to 40 J/cm2 of 365 nm light resulted in
photo-restoration of cage-inactivated ISIS 2302 antisense activity in 56.7 ± 5.9% of HeLa cells.
There was no significant difference in ICAM-1 expression between cells treated with 40%-caged
antisense and cells treated with no antisense. Subsequent exposure to 40 J/cm2 365 nm light
resulted in a significant increase in antisense activity from the cells treated with 40%-caged
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antisense. This work demonstrates the in vitro use of a light inducible system for achieving the
spatio-termporal control of antisense specific activity.
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CHAPTER I
BACKGROUND AND INTRODUCTION
Introduction
Caged compounds are an optically-active class of chemicals that have been designed to
respond to light in the UV and near-UV range. Upon exposure to light, the photolabile bond
between the cage species and its target molecule is cleaved, releasing the target molecule to its
“native” original, bioactive form.

Photosensitive cage compounds have been shown to

successfully inactivate DNA plasmid activity in vitro and in vivo (Monroe, McQuain, et al.,
1999). The mechanism of inactivation involves the covalent attachment of a chemical cage
species to the DNA effector molecule via a photolabile bond. The subtle influence of the cage
group on the structure of the DNA molecule renders DNA biologically inert. The cage
compound 1-(4,5-dimethoxy-2-nitrophenyl)ethyl ester (DMNPE) has previously been used in
the

control

of

various

biological

molecules

including

ATP

and

phosphodiester

oligodeoxynucleotides (ODNs) (Kaplan, Forbush, et al., 1978; Walker, Reid, et al., 1988; Ghosn,
Haselton, et al., 2005). The high efficiencies achieved in cage reactions involving 20 mer ODNs
suggested that ODNs of the same sequence but having modified backbone structures would also
be suitable candidates to be cage-inactivated by DMNPE. Preliminary investigations showed
that the hybridization activity of the phosphodiester ODNs could be significantly reduced
through the attachment of DMNPE and that this activity can be photo-restored through exposure
to near-UV light (Ghosn, Haselton, et al., 2005). Achieving control over the hybridization
abilities of nucleic acids translates to control over biological activity and gene expression.
One area of potential use of caging chemistries is in achieving the targeted delivery of
antisense therapeutics. Antisense gene therapy has evolved out of a refocusing of medicinal
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therapeutic strategies from the protein to the DNA level. Antisense strategies offer the advantage
of specificity with direct targeting of diseased and damaged genes. However, the current
challenge in the implementation of antisense therapeutics lies in achieving spatial and temporal
control over the range of their inhibitive effects.

Cage-inactivation and subsequent photo-

restoration of antisense agents is one possible means of achieving this control. ISIS 2302 is one
such antisense agent, a 20-mer phosphorothioate DNA sequence, which suppresses the cell
surface expression of Intracellular Adhesion Molecule-1 (ICAM-1) in vivo.

For in vitro

experimentation, ISIS 2302 has been shown to suppress ICAM-1 expression in cells stimulated
with various cytokines, including Interferon-γ, tumor necrosis factor-α, and interleukin-1β
(Dustin, Rothlein, et al., 1986; van de Stolpe, van der Saag, 1996). This study proposes to test
the effectiveness of a cage-inactivated ISIS 2302 antisense system in cell culture and
demonstrate that significant photo-restoration of antisense activity can occur with minimal cell
damage through the optimization of caging reaction conditions.
The Promise of Gene Therapy: Prophylactic Action
Conventional drug therapies are designed to target post-translational products in their
direction to quench the effects of mutations, disease, and infections. Gene therapy treatments
have advanced the potential of drug therapy through their mechanism of action which works to
inhibit the expression of a mutation that is causing a particular disease or infection rather than
treating the effect of the mutation. In addition, the high specificity associated with genetic
treatments offers the additional advantage of decreased incidence of the side effects that are
commonly associated with conventional therapeutics. The general goal of gene therapy is to treat
disease, either by curing the disease or slowing progression, through the introduction of specific
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genetic materials targeted to specific cells or tissues (Mulligan, 1993). Genetic treatments may
involve nucleic acids in the form of antisense oligodeoxynucleotides, double-stranded plasmids,
DNA aptamers, or DNAzymes which work through cleavage or splicing mechanisms, or as RNA
in the form of ribozymes which are enzymatically active RNA, RNA aptamers which work
through direct protein inhibition, or RNA interference (Patil, Rhodes, et al., 2005).
Implementation of these genetic strategies depends on the ability to introduce transgenes into
cells. Introduction of these genes in naked form to solutions in cell culture rarely results in
successful uptake and there is minimal endosomal release of the few internalized ODNs (Patil,
Rhodes, et al., 2005; Roth, Sundaram, 2004). Therefore, a delivery mechanism is necessary to
transport and establish transgenes in cells. Gene therapy delivery systems fall into one of two
major classifications: physical techniques or vector delivery techniques. Physical techniques
refer to the delivery of naked ODNs via microinjection, particle bombardment, electroporation
and other such strategies. The major advantages of these systems are the very high level of
specificity in delivery, ability to achieve single cell targeting, and, with the exception of
bombardment techniques, high efficiency. Despite these advantages, practical considerations
concerning ease of use, transfection time and, risk to cell viability render them less desirable
candidates as delivery systems than the vector techniques in many applications (reviewed by
Wells, 2004; Patil, Rhodes, et al., 2005).
Alternatively, vector systems, though less efficient, offer the advantages of being noninvasive and providing additional protection from nuclease digestion. Vector systems can be
classified as either viral or non-viral vectors and have been reviewed by Patil et al (Patil, Rhodes,
et al., 2005). Adeonviral vectors are double-stranded DNA vectors that are popular due to their
3

efficiency and ability to transmigrate dividing and non-dividing (senescent) cells (Liu,
Nakamura, et al., 2006). However, adenoviral vectors are highly immunogenic and desired
genetic effects are rapidly neutralized through their uptake by the reticuloendothelial system and
liver (Liu, Nakamura, et al., 2006). Adeno-associated vectors are single-stranded relatives of
adenoviral vectors that have reduced risk of inciting an acute immune response. However, their
use is limited by small loading capacity and restrictions on the types of cells that they can
transfect (Nicklin, Buening, et al., 2001). Retroviral vectors offer the advantage of being able to
sustain expression due to integration into the cellular genome. In addition, retroviral vectors can
be specifically targeted to various tissue types, but even so these vectors preferentially uptake
into rapidly dividing cells. The disadvantage to the use of retroviral vectors is the increased risk
of cancer development, specifically leukemia (Liu, Nakamura, et al., 2006). Lentiviral vectors
are a subclass of retrovirals that are specifically derived from the human immunodeficiency virus
and have the ability to transfect non-dividing as well as dividing cells.

However, the

disadvantage to these vectors is their lack of targeting ability, especially when target cells are
dispersed throughout the body.
Natural and synthetic polymers, lipids, and ligands are several types of non-viral vectors used
for DNA transport.

Polymeric delivery systems are well studied and nano-technological

advances have broadened their applicability through the fine-tuning of hydrolysis and diffusion
rates. A biodegradable polymer can be chosen such that specific release rates can be achieved
while protecting the entrapped ODNs from nuclease digestion. Many commercially available
DNA transfection agents are composed of neutral, anionic, and/or cationic lipid derivatives.
Cationic liposomes are easy to use due to their self-assembling nature allowing DNA complexes
to be formed relatively quickly and achieve high transfection efficiencies (Roth, Sundaram,
2004). However, the efficiencies achieved with any delivery system depend on experimental
4

conditions. Choice of cell type, incubation times, and most importantly, the class and chemical
makeup of the nucleic acid being used will influence the effectiveness of the carrier system.
Gene Silencing: Antisense
Antisense is a sequence-specific form of genetic therapy that works towards inhibiting target
gene expression. Antisense agents utilize specific sequence information derived from functional
genomics and thus have very high specificity and broad applicability in a variety of areas from
target validation to therapeutics (Kurreck, 2003; Bennett, Cowsert, 1999). The antisense mode
of action is based on the central dogma of molecular biology which describes protein production
though DNA transcription and RNA translation. During transcription, DNA localized in the
nucleus is unwound gene-by-gene into two individual strands, a sense and an antisense strand.
Messenger RNA (mRNA) is created from the sense strand of the unwoven DNA molecule. Once
the complete gene has been transcribed, the mRNA migrates from the nucleus into the cytoplasm
and conjugates with ribosomes.

The mRNA-ribosome complex translates the information

encoded on the mRNA to produce nucleic acids that are elongated to form a protein.
Antisense strategies modulate protein production through the down-regulation of gene
expression based on selective inhibition. Antisense technology is based on the generation of a
short nucleotide sequence (between 15 – 25 base pairs) which is complementary to a target
mRNA sequence (Cook, 1993). These highly specific sequences are synthetically engineered to
model regions on the non-coding strand of unwound DNA double helix and are therefore
complementary to specific mRNA sequences. With the elucidation of the complete human
genome, an antisense ODN could conceivably be designed to target any gene combination to
treat any disease.
Once introduced into the cell, the antisense ODN binds to the target mRNA via Watson-Crick
hydrogen bonding.

The resulting heteroduplex works to inhibit translation by one of two
5

methods. One route of antisense activity is through the steric blockade of translation at the
ribosome. Initial observations of antisense effects were demonstrated when researchers observed
the inhibition of Rous sarcoma virus replication by a complementary oligonucleotide through
this steric blockade mechanism (Zamecnik, Stephenson, 1978). The second and more powerful
means of antisense activity is the induction of ribonuclease H (RNase H)–dependent cleavage of
mRNA. When antisense ODNs bind to their mRNA target, the double-stranded complex that is
formed though the binding of mRNA to the antisense ODN is a cellular aberrance that stimulates
the activity of RNase H. The RNase H enzyme selectively degrades the mRNA strand of the
mRNA-ODN heteroduplex and releases the antisense ODN into the cytoplasm to bind to its next
target (Nakamura, Oda, et al., 1991; Wu, Lima, et al., 2004). One of the advantages of the
RNase H mechanism is that ODN association with mRNA offers the ODN protection from
nuclease digestion.
In general, there are several requirements that an antisense therapeutic needs to meet and
certain characteristics that define their effectiveness.

Antisense ODNs must be able to get

through the cell membrane, be able to integrate with the aqueous environment, and have the
ability to distribute to the cell cytoplasm and/or nucleus where their effects are carried out. In
order to produce any effect, the ODN needs to have an improved resistance to nuclease
degradation without compromising its specificity or its binding affinity to the target mRNA. In
comparisons between mechanisms of inhibition, it is generally desirable that the ODN induce
RNase H target degradation (Grunweller, Wyszko, et al., 2003) despite the rare exceptions where
steric inhibition has been shown equally potent (Kurreck, Wyszko, et al., 2002).
Antisense Oligonucleotide Variations
Chemical modifications to AS ODNs are designed to promote the characteristics outlined
above to enhance their effectiveness.

Limitations associated with the biostability of normal
6

phosphodiester AS ODNs are related to the poor in vivo half-life due to their rapid degradation
by both extraellular and endocellular nucleases (Cook, 1993). Nuclease affinity for antisense
agents can be greatly reduced though the modification of the phosphodiester backbone.
Modifications to the physical structures of antisense ODNs typically involve replacing one of the
non-bridging oxygen atoms with an alternative chemical group. Several of these chemical
modifications are shown in Figure 1.1.

First generation structural modifications include

phosphorothioate

which

ODNs

(PS

ODNs),

have

sulfur-substituted

linkages,

and

phosphorodiamidate morpholinos, shown in Figure 1.1. Phosphorothioates have been the most
extensively studied modification due to the ease of synthesis and their commercial availability.
Phosphorothioates also remain the most widely employed antisense therapeutic as they are one
of the few modifications whose chemical makeup is a suitable substrate for RNase H (Wu, Lima,
et al., 2004;Kurreck, 2003). In addition, the increased nuclease resistance of phosphorothioate

Figure 1.1. Oligonucleotide Backbone Modifications
ODNs allows for an intracellular half-life on the order of several hours compared to only several
minutes with normal PD-ODNs (Maksimenko, Gottikh, et al., 1999). However, PS ODNs have
disadvantages associated with compromised binding affinity and reduced specificity for the
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target mRNA resulting from the increased binding affinity for certain proteins in the extracellular
matrix, blood plasma, and serum (Brown, Kang, et al., 1994; Maksimenko, Gottikh, et al., 1999).
In addition, uncertainty concerning basic mechanisms of action has caused some concern about
the possible toxicity of PS ODNs as they are degraded (Crooke, 2004). However, oxidation of
thiol groups on the PS backbone result in normal phosphodiester structure with no inherent
toxicity (Crooke, 2004).
Second and third-generation modifications likewise have increased nuclease resistance and
may offer improved specificity over first-generation phosphorothioates. An in-depth study of a
second-generation modification in which a PS is modified with a 2’-O-methyl chimera
demonstrated equal cellular stability and a ten-fold increase in target specificity over that
achieved with an unmodified PS (Yoo, Bochkareva, et al., 2004). In this comparative study
between first-generation unmodified PS and second-generation 2’-O-Methyl modified PS, Yoo
et al were able to quantify the decrease of RNase H activation reporting a 50% decrease in
mRNA target degradation when the modified PS ODNs were used (Yoo, Bochkareva, et al.,
2004).

Likewise, third-generation modifications, such as peptide nucleic acids (PNAs) and

morpholinos have received notable attention for both their high specificity and definitive nontoxicity (Nesterova, Cho-Chung, 2004; Summerton, 1999). In addition, both of these modified
ODNs are completely resistant to nuclease digestion because, in the case of PNAs, the entire
phosphate backbone has been replaced with peptides, and in the second case, the ribose has been
replaced with a morpholino group thus rendering both unrecognizable by nucleases. However,
there have also been cases of evidence to the contrary in which the long-term effectiveness of PS
ODNs dominates over several other modification types including PNAs (Gray, Basu, et al.,
1997). It is difficult to achieve a true comparison of efficacies between the uncharged thirdgeneration

PNAs

and

morpholinos

and

the
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negatively

charged

second-generation

phosphorothioates because of the extreme differences in the delivery techniques which work best
for each in vitro. In addition, there are also other limitations associated with the use of newer
generation modifications, concerning solubility, uptake issues and, most significantly, their
inability to induce RNase H activity and thus reliance on inhibiting translation via steric
hindrance. Specifically, it has been shown that morpholinos must be specifically targeted to a
region within 25 bases of the 5’ cap, i.e. prior to the initiation complex, of a target mRNA to
effectively reduce gene expression, unlike PS ODNs which work via RNase H mechanisms and
can affect entire gene transcripts (Summerton, Stein, et al., 1997; Summerton, 1999). Despite
their inability to induce the RNase H mechanism, evidence of their superior target specificity and
total resistance to nuclease digestion, as referenced above, make morpholino ODNs an attractive
alternative to PS ODNs as their use in antisense research has become increasingly economically
feasible and alternative methods to scrape-loading cell delivery due to, the development of
compatible transfection lipids, have emerged (Takei, Kadomatsu, et al., 2005; Morcos, 2001).
Locked nucleic acids (LNAs) ODNs are another class of third-generation analogues that have
gained recent popularity.

LNAs incorporate ribonucleotide bridges into phosphodiester or

phosphorothioate ODNs to promote greater resistance to nuclease degradation. LNAs have high
target affinity, good cellular uptake, and are known to activate RNase H (Orum, Wolter, et al.
2003; Kurreck, Wyszko, et al., 2002). Studies involving the specific comparison of 20-mer LNA
ODNs against a 20-mer phosphorothioate ODN to Intracellular Adhesion Molecule-1 (ICAM-1),
ISIS 2302, in human umbilical vein endothelial cells (HUVECs) showed that the LNAs were as
effective in inducing RNase H activity and target mRNA degradation as ISIS 2302 (Obika,
Hemamayi, et al., 2001).
Another antisense modality that has had more notable focus and generated a great deal of
excitement in recent years is RNA interference (RNAi), a wholly RNA-based antisense
9

mechanism discovered by Fire and colleagues (Fire, Xu, et al., 1998). The RNAi mechanism
involves long double-stranded RNA (dsRNA) which is intracellulary processed into small
interfering RNA (siRNA) by the dicer enzyme. siRNAs then induce gene silencing through the
stimulation of RNA-induced silencing complex (RISC) mRNA degradation (Hammond,
Berstein, et al., 2000). Just as the DNA-RNA antisense hybrid induces RNase H degradation of
target mRNA, so does the RISC complex recognize the double-stranded RNA molecule and
selectively degrade the target mRNA and free the antisense siRNA to bind another target
(Tomari, Zamore, 2006). Similar to DNA antisense modifications, chemical modifications to
RNA nucleotides, such as 2’-O-methyl groups, can increase the duration of siRNA antisense
activity (Amarzguioui, Holen, et al., 2003). One of the major advantages to siRNA is that the
inhibitive effects may be more potent and longer lasting than the short-term range of effects seen
with AS ODNs. However, AS ODN effects are more immediate whereas siRNA has a longer
refractory period, a characteristic supported by the results of RNAi/AS ODN GFP knockdown
comparison studies done in HeLa cells (Bertrand, Pottier, et al., 2002).
Comparisons between LNAs, siRNAs and PS ODNs determined siRNAs to be the most
effective inhibitor of gene expression, but confirmed that PS ODNs and LNAs are less
expensive, easier to handle, and have much greater stability in cell culture, compared to siRNAs
which have a half life of <2 hours in HeLa cells (Grunweller, Wyszko, et al., 2003). Similiarly,
comparative studies of siRNA and 2’-O-mehyoxyethyl modified PS ODNs targeting human
Intracellular Adhesion Molecule-1 (ICAM-1) suggest that siRNA and AS ODN mechanisms
may have comparable potencies, specificities, and duration of effects therefore demonstrating
that, while RNAi has generated a lot of excitement, AS ODNs are still one of the leading forms
of genetic therapy (Vickers, Koo, et al., 2003).
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Although backbone modifications have improved the long-term impact of AS ODNs on gene
expression, rapid nuclease digestion is not the only factor limiting intracellular effects. An indepth study modeling the effectiveness of antisense ODNs indicated that ODN activity is also
highly dependent upon the rate at which mRNA hybridization occurs as well as on the ability of
the ODN to prevent or escape entrapment in endosomes (Roth, 2005). Subtle alterations to
antisense ODNs could affect their response kinetics and hybridization abilities. Once
internalized, ODNs are frequently held up in internal vesicles such as lysosomes, endosomes,
and the endoplasmic reticulum before they make their way into the cytoplasm where they take
effect (Akhtar, Hughes, et al., 2000). In addition, studies involving T-lymphocytes showed that
many mRNAs, though CD54 was not specifically studied, that are involved in immunological
and inflammatory responses have very short half-lives and thus do not provide a large window of
opportunity for hybridization to occur (Raghavan, Ogilvie, et al., 2002).

Therefore, for

antisense ODNs to impart any influence towards the suppression of these rapidly expressed
genes, the ODN must have a very rapid hybridization rate and its activity can not be impeded by
entrapment and compartmentalization.
Antisense Delivery Techniques
While backbone modifications have increased the long-term effects and potency of antisense
technologies, the transport of the polyanionic ODNs through the phospholipid membrane into the
cell is another problem that must be addressed. Although it is possible that small ODNs may
have the ability to find cationic regions on the cell membrane and enter via endocytosis, the
efficiency of uptake is low when compared to delivery efficiencies and cellular accumulation
achieved through the use of carriers (Nakai, Seita, et al., 1996; Roth, 2005). In addition, if they
are internalized, many of these therapeutics are susceptible to degradation by intracellular
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nucleases or incarceration in lysosomes and endosomes (Hughes, Hussain, et al., 2001; Akhtar,
Juliano, 1992).

Therefore, the successful implementation of antisense therapies requires a

delivery vehicle which can improve cellular uptake and transfection efficiency.
Oligonucleotide delivery typically consists of carrier-mediated techniques involving
conjugation to cationic lipids, polymers, proteins, and other hydrophobic constructs to facilitate
ODN transport into the cell. Cationic lipids form lipoplexes with nucleic acids that promote
cellular internalization through electrostatic interactions with ODNs that cause ODNs to become
encircled in an aqueous layer surrounded by a cationic bilayer that can associate with the
negatively-charged cell membrane (Hughes, Astriab, et al., 2000).

Lipoplexes such as

dioelylphosphatidylehanolamine (DOPE) are commercially available in variety of different
formulations and may also facilitate the release of ODNs entrapped in endosomal and lysosomal
compartments through membrane disruption (Akhtar, Hughes, et al., 2000). The advantage of
lipid systems is that they are known to be biocompatible as they are relatively safe and
nonimmunogenic (Bartsch, Weeke-Klimp, et al., 2005; Akhtar, Hughes, et al., 2000). Recent
works have shown the successful in vivo delivery of Intercellular Adhesion Molecuel-1 (ICAM1) antisense ODNs to endothelial cells through conjugation with Stabilized Antisense Lipid
Particles (SALPs) which can be targeted to specific receptor sites using a combination of lipids
(Bartsch, Weeke-Klimp, et al., 2005). Unfortunately, while this study demonstrated precise
delivery of antisense ODNs to target cells, they were unable to achieve target gene inhibition of
human ICAM-1.
This introduces one of the main limitations with conjugation techniques, which is that they
rely on surface recognition receptors to achieve targeted delivery (Akhtar, Hughes, et al., 2000).
As in the aforementioned case, not only is this method unreliable, but in antisense therapies, this
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can introduce another complication in that both healthy and target cells express the specific
ligand and thus both cell types would receive treatment. In addition, unique ligands must be
determined for each targeting application. Therefore, receptor-ligand interactions as a means of
achieving targeted antisense drug delivery are insufficient to achieve both spatial and temporal
control of antisense effects. These issues exist in reference to a variety of ligand conjugates,
including cholesterol, glycoproteins, and antibodies that have been used for targeting where
many of these conjugates were shown to be unique to specific receptors in specific cell systems
(reviewed in Roth, 2005).
Antisense Limitations
Despite the enormous potential of antisense therapeutics, employment of these strategies in
vivo has encountered several problems concerning AS ODN biological stability, toxicity, cellular
uptake, and targeted delivery issues. Even with improvements to the biological stability of many
classes of AS ODNs, drug development is still limited by insufficient delivery of gene-based
therapeutics, targeted delivery issues, and ineffective intracellular distribution even after
successful transfection is achieved. Different carriers such as cationic lipoplexes have resulted in
improved delivery of antisense molecules, but non-specific delivery to cells and tissues outside
of the targeted area have resulted in high background signals in ODN tracking and imaging
studies (Zhang, Rusckowski, et al., 2001). This high background signal corresponds to high
levels of non-specific accumulations of antisense drugs in healthy tissue. In order to avoid
potentially harmful effects, a delivery methods needs to be developed that can provide precise
and accurate control over the spatiotemporal effects of antisense therapeutics. One possible
means to target antisense activity is to chemically inactivate antisense ODNs, deliver these
inactive species systemically, and re-activate them at select sites with light exposure, which can
be easily controlled.
13

Photosensitive Cage Compounds
The chemical inactivation scheme proposed in these studies employs cage compounds which
are essentially photoremovable protecting groups. These photoremovable protecting groups are
chemical species that can be covalently attached to a target molecule via a photolabile bond
(Kaplan, Forbush, et al., 1978). The biological application of cage technology is that these
protecting groups suppress the biochemical function when associated with the target molecule.
These cage species are designed to respond to a specific wavelength of light such that, upon
irradiation, the cage group is released and the biomolecule is liberated and its biological activity
restored (McCray, Trentham, 1989). Cage groups are generally responsive to wavelengths in the
300-380 nm range of light (Bernardinelli, Haeberli, et al., 2005).

Light in this range will have

little effect on the attached biomolecule or on the chemical structure as a whole other than the
photoreacting species.

Desired cage characteristics include a high extinction coefficient,

corresponding to strong light absorption characteristics, as well as a high quantum yield, which
dictates energy conversion efficiency. Like the antisense agents they are caging, the cage
compounds must be water-soluble and both the cage and its byproducts should be biologically
inert.
Initial studies demonstrating cage attachment to biomolecules involved the use of a
nitrobenzyl derivative, 1-(2-nitrophenyl) ethyl (NPE), to inactivate ATP and subsequently
photorelease the ATP to its bioactive form by exposure to 340 nm light (Kaplan, Forbush, et al.,
1978). Although these nitrobenzyl groups were the first and remain a very popular class of cage
compounds, the number and variety of available cage groups that exhibit control of bioactivity is
expanding such that researchers are afforded more options in choosing cage group
characteristics. Since the work by Kaplan et al, several different cage groups have demonstrated
similar success in the inactivation and photoreactivation of ATP, as seen in Figure 1.2 where a
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dimethoxylated nitrobenzyl group responsive to 365 nm light was used. These acetomethylated
versions of nitrobenzyl groups are employed more frequently in cellular studies due to the
increased cell permeability of the molecule and lessened biological effects of 365 nm light
compared to shorter wavelengths.

Figure 1.2. Photolysis of DMNPE-Caged ATP

These nitrobenzyl derived groups remain popular as other commonly used cage groups
respond to light in the UVB range (290-320 nm) which may cause more direct cellular damage
than UVA light (320-400 nm) (McCray, Trentham, 1989). The specific nitrobenzyl derivative
used in these studies, 1-(4,5-dimethoxy-2-nitrophenyl) ethyl ester (DMNPE) is known to
specifically absorb light at 355 nm and, as shown in Figure 1.3, based on known adduction sites
on other biomolecules, the theorized attachment site for DMNPE on nucleic acids is the
phosphate backbone of the DNA molecule (Walker, Reid, et al., 1988). Since these studies,
significant progress has been made towards achieving site-specific attachment of cage groups to
areas other than the phosphate groups.

Caging of specific bases in various nucleic acid

analogues has been accomplished with cage attachment to adenosine in DNAzymes and to
thymidine bases in both phosphoramidites and aptamers (Chaulk, MacMillan, 1998; Heckel,
Mayer, 2005; Mayer, Heckel, 2006).
Applications of cage groups have expanded beyond their beginnings in organic synthesis to
include to play important roles in the inactivation of various proteins, muscle fibers,
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neurotransmitters, elementary regulatory molecules such as Ca2+, fluorophores, lipids, and, most
recently, nucleic acids (Cohen, Stoddard, et al., 1997; Aarhus, Gee, et al., 1995; Schworer, Wirz,
2001). The caging of DNA to block genetic activity has demonstrated use in the inactivation of
Green Fluorescent Protein (GFP) plasmids using DMNPE (Monroe, McQuain, et al., 1999).
Subsequent studies have expanded the ability of DMNPE to cage nucleic acids as demonstrated
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Figure 1.3. Photolysis of DMNPE-Caged PS DNA
in the reversible control of the hybridization ability of DNA oligonucleotides and the ability to
cage siRNA (Ghosn, Haselton, et al., 2005; Shah, Rangarajan, et al., 2005). However, the use of
nitrobenzyl groups is limited by concern about possible cytotoxic byproducts of photolysis
reactions, such as the formation of nitrosobenzaldehyde (DMNBB) or nitrosoketone (DMNPE),
leading to the development of other photoprotective groups.
There are a great variety of photoprotecting cage groups that have been developed outside of
the nitrobenzyl family. One example is the brominated 7-hydroxycoumarin-4-methyl (Bhc)
cage. Bhc groups have achieved success in the caging of carboxylic acids and may offer the
16

advantage of having photosensitivity in the infrared wavelength range using two-photon
excitation (TPE) (Furuta, Wang, et al., 1999; Banjeree, 2003). TPE occurs when two longwavelength photons are simultaneously (10
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s) absorbed by a fluorescent molecule. This

allows for the use of low-energy wavelengths like IR, which are capable of deeper tissue
penetration and minimized photobleaching affects (Denk, Strickler, et al., 1990; Diaspro,
Robello, 2000). The advantage of two-photon excitation is the decreased time of cell culture
irradiation due to dual photon energy absorption. However, there is minimal evidence to support
the theory that a protective group that has very low quantum efficiency in the UV range is going
to react with higher quantum energy in the IR range through the use of the two-photon system.
In a study by Zhao et al, they presented the first example of the photolysis of a a 1-(2nitrophenyl)ethyl (NPE) cage group with infrared light via a TPE system (Zhao, Zheng, et al.,
2004).

The NPE group was associated with a coumarin molecule was shown to have

surprisingly high photolysis efficiency at 365 nm, a phenomena that was enhanced through the
implementation of a TPE system with 740 nm light (Zhao, Zheng, et al., 2004). Photolysis
efficiency was measured as a product of the quantum yield and the extinction coefficient of a
cage molecule at a specific wavelength.

However, the use of this group was specifically

intended for use with a fluorescent coumarin substrate for in vivo imaging applications as
compared to the NDBF and Bhc caged groups which have potential applicability to other
biomolecules (Zhao, Zheng, et al., 2004; Momotake, Lindegger, et al., 2006; Furuta, Wang, et
al., 1999).
Denk et al were able to conclude that photorelease of ATP from the DMNPE caged form is
much faster and can be accomplished in smaller volumes using TPE (Denk, Strickler, et al.,
1990). However, the aforementioned Bhc groups have slower release kinetics and are still used
in single-photon excitation with quantum yields similar to that achieved with DMNPE (Banjeree,
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2003). One of the most recent cage groups to be developed is a nitrodeibenzofuran (NDBF)
group that has been shown to be up to 160x more efficient in photolysis than other nitrobenzylderived cages (Momotake, Lindegger, et al., 2006).

The NDBF group has demonstrated

quantum yields of up to 0.7 and extinction coefficients of 18,400 M -1cm-1 when reacted with
Ca2+ and has the ability to undergo two-photon excitation at 350 nm. This can be compared to
the extinction coefficient of 4795 M -1cm-1 reported for DMNPE nucleic acid studies (Ghosn,
Haselton, et al., 2005). The advantage of having two-photon excitation capabilities is that less
energy per photon is needed to photocleave the protecting group, therefore is a decreased risk of
cellular damage as demonstrated with the NDBF cage which has confirmed compatibility with
cell systems and shows promise for in vivo applications (Momotake, Lindegger, et al., 2006).
In addition, advances in solid-phase ODN synthesis have enabled individually caged
nucleotides to be incorporated into oligonucleotides and have proven to be compatible with
fluorophore-quencher conjugation allowing for real-time monitoring of cage release (Tang,
2005).

This innovative caged fluorescent oligodeoxynucleotide consists of a fluorophore

adjoined to a DABSYL quencher and a PC linker which responds to 365 nm light. Results of
these studies show a 95% release of active biomolecule based upon fluorscein response alone
and, if conjoined with in vitro studies to demonstrate restoration of biomolecule activity, could
be used to offer additional support of the efficacy of antisense treatments.
The success achieved in these studies indicates that the employment of photoremovable cages
may provide a means of achieving spatial and temporal control of biofunctionality. Caged
molecules can be delivered systemically throughout a biological system in a bioinactive form.
Spatio-temporal control of activity can subsequently be elicited through the photoexposure of
targeted cells and tissues.

For example, UVA light has been used to achieve targeted retinal

intravascular photoactivation of thrombin from a methylcinnamate cage (Arroyo, Jones, et al.,
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1997 ). As previously mentioned, one of the important characteristics of these cages is that they
have high energy conversion efficiencies in order to limit cellular exposure to damaging UV
light. Newer cage groups have received more significant interest due to reportedly improved
photochemical characteristics compared to characteristics of DMNPE-ATP (Wooton, 1989).
However, more recent experiments involving caged NAD, NADP and the antibiotic doxycycline
have indicated that DMNPE release rates and product formation may have better photochemical
characteristics than what was once thought, indicating that these characteristics may simply be
dependent upon the moiety being caged (Cohen, Stoddard, et al., 1997; Cambridge, Geissler, et
al., 2006). Experiments with NAD and NADP were able to achieve photolysis rates of 1.7E 104
– 1.8E104 (s-1) and quantum yields of 0.17 and 0.19, values almost twice that of which could be
achieved with α-Carboxy-2-nitrobenzyl (CNB) group (Cohen, Stoddard, et al., 1997). Similarly,
DMNPE-caged doxycycline achieved yields of 0.013-0.075 with no reported measurements of
release rates (Cambridge, Geissler, et al., 2006). Interestingly, in this experiment, the reaction of
DMNPE with doxycycline produced two different stable diasteromers of the caged product, only
one of which demonstrated acceptable suppression of genetic activity.

Reactivation was

subsequently achieved upon exposure to UV light in the 300-400 nm range.
Limitations to Caging
It has been noted that DMNPE-caged nucleotides may be prone to hydrolysis and thus result
in a caged-product that has residual native ODNs in solution (Wootton, Trentham, 1989). In
order to avoid the resulting system “leaks” where some ODNs retain their hybridization ability,
complete ODN inactivation require the attachment of a minimum number of cage groups.
However, excessively caged ODNs may require large doses of light and make achieving any
degree of photo-restoration difficult.

This effect was demonstrated when DMNPE-caged

plasmids were transfected into HeLa cells and exposure to UV light resulted in only partial
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restoration of bioactivity (Monroe, McQuain, et al., 1999). Limiting the amount of the DMNPE
group that is added to the ODN solution restricts the number of cage groups bound to each
individual ODN.

While this is advantageous to achieving successful photocleavage, the

disadvantage is that a number of the ODNs in the solution may have only few cage groups
attached and may still be able to hybridize.

This contributes to the system leak with

hybridization occurring in the uninduced state. In order to fully optimize the use of cage
compounds to both inactivate and subsequently reactivate biomolecules upon light exposure,
excess cage and non-caged samples are removed from the reaction products.
The other main limitation to the use of cage compounds is that cellular exposure to UV light is
known to induce cytotoxic effects over long periods. A potential solution to this problem would
be to use cage groups that are photoresponsive to longer, less damaging wavelengths. However,
cage groups, such as nitroindolines and the phenacyl group, that are known to be responsive in
the visible region have slow release kinetics, in the magnitude of minutes and many are not water
soluble (Shembeckar, 2005; Banerjee, Grewer, et al., 2003). Therefore, the majority of cage
groups used in biological applications respond to UV light. UV responsive groups that have
sufficiently high quantum yields have been shown to be photolyzed with light in the
infrared/visible wavelength range using two-photon excitation (Fedoryak, Dore, 2002; Zhao,
Zheng, et al., 2004; Furuta, Wang, et al., 1999; Momotake, Lindegger, et al., 2006).
Antisense in Action: Targeting Crohn’s Disease
Antisense strategies have obvious applications in the targeting of mutated genes and disease
causing proteins. However, another area of potential importance for antisense therapy is in the
suppression of immune responses.

Transplantations, autoimmune diseases, and chronic

inflammation involve the induction of a normal cascade of events within the immune system.
Vitravene (formivirsen sodium) is an 21-mer phosphorothioate antisense therapeutic developed
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by ISIS pharmaceuticals for the treatment of cytomegalovirus retinitis, characterized by retinal
inflammation, and is the first and only antisense drug to have received FDA approval in the
United States (de Smet, Meenken, et al., 1999; Crooke, 1998) As of 2005, there were five other
oligonucleotide antisense therapeutics involved in phase 3 clinical trials and expecting FDA
approval (Patil, Rhodes, et al., 2005).

Figure 1.4. ISIS 2302 Antisense Mechanism of Action Against ICAM-1
Cationic lipid conjugation facilitates ICAM-1 asODN cellular entry.
Inside the cell, phosphorothioate modifications help protect the asODN
from nuclease digestions. The asODN is specifically targeted to ICAM-1
mRNA, which it binds to by shuttling between the cytoplasm and nucleus
resulting in target degradation by the RNase H enzyme and reduction of
ICAM-1 protein expression on the cell surface.
Of these antisense drugs awaiting FDA approval, only one is indicated for the treatment of a
non-cancer condition. Alicaforsen (ISIS 2302) is the first antisense agent to be targeted to a
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gastrointenstinal disease (Caprilli, Viscido, et al., 2002). ISIS 2302 is a 20-mer phosphorothioate
antisense oligodeoxynucleotide complementary to ICAM-1 and designed to treat Crohn’s
Disease (Figure 1.4).

Crohn’s is an inflammatory condition characterized by persistent

leukocyte presence in gastrointestinal tissue (Yacyshyn, Barish, et al., 2002).

Leukocyte

recruitment to tissue is the result of a cascade of immunological events. Though the trigger for
this cascade is unclear, there are a variety of cytokines and intercellular adhesion molecules
involved in the process that can be targeted with antisense molecules. In particular, the disease is
characterized by a marked increase in intercellular adhesion molecule-1 (ICAM-1/CD 54)
expression on the surfaces of cells in the ileum, colon, and peripheral blood local to the intestinal
area. ICAM-1 is a transmembrane cell surface protein that is a member of the immunoglobulin
superfamily whose up-regulation is cytokine inducible (Chiang, Chan, et al., 1991). This
inducible expression is mediated by several different proinflammatory cytokines in a number of
different cell types (Dustin, Rothlein, et al., 1986; Nedbal, Cho-Chung, 2002; Lucas, Van
Rompaey, et al., 2004). Interferon-gamma (IFNγ) is a particularly potent moderator of ICAM-1
expression which will be used in these experiments to up-regulate gene expression.

Once

introduced to the cell, IFNγ activates the Janus Kinases (JAK)-signal transducers and activators
of transcription (STAT) pathways leading to the interferon response element (IRE) located 100
base pairs away from the ICAM-1 promoter site (Roebuck, Finnegan, 1999). ICAM-1 upregulation results in increased leukocyte migration from the vasculature to inflamed tissue sites
and is correlated to increased activity of Crohns’s disease (Yacyshyn, Chey, et al., 2002).
ISIS 2302 is a documented substrate for RNase H (Lebedeva, Stein, 2001; Walder, Walder,
1988).

A study to determine the pharmacokinetics and effectiveness of ISIS 2302 in the

treatment of Crohn’s, results confirmed that ISIS 2302 suppresses cytokine-inducible up-
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regulation of ICAM therefore resulting in disruption of the immune cascade and inflammation
reduction (Yacyshyn, Chey, et al., 2002).
Project Aims
The hypothesis of this study was that the inactivation of antisense ODNs through the covalent
attachment of a caged compound can be reversed with exposure to near-UV light in vitro to
restore bioactivity through the optimization of two parameters: (1) minimization the number of
attached cage groups required for antisense inactivation and (2) subsequent minimization of
cytotoxicity due to photoexposure. The specific objectives of this project were to assess caging
efficiencies through absorbance spectrophotometry and gel electrophoresis to determine degrees
of cage-inactivation of ODN products.

We also proposed to evaluate the affect of cage

attachment on hybridization activity using molecular beacon based assays and experimental
modeling. Additional objectives of this project were to evaluate the effects of other experimental
conditions, including UVA light and transfection lipids, on cell systems. Light-dose responses of
inducible ICAM-1 expression in HeLa cell cultures were studied in order to determine how
successful photoactivation of caged PS AS ODNs could be achieved with minimal affect of cell
culture. In meeting this objective we will show that cage techniques can be utilized as a means
of achieving spatial and temporal control of antisense activity. Overall, we will demonstrate the
ability to use engineering principles to overcome the inherent challenges in achieving specific
and controlled effects in cell and tissue systems.
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CHAPTER II
IN VITRO CONTROL OF ANTISENSE ACTIVITY USING CAGED
PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES
Introduction
There is great potential in the use of oligonucleotide (ON) antisense agents in the
treatment of various diseases and genetic disorders. Antisense agents are synthesized short,
single-stranded RNA or DNA nucleotide sequences that are complementary to target mRNA or
DNA sequences.

Hybridization of antisense drugs to their targets in the nucleus and/or

cytoplasm results in translation inhibition. There are a number of different classes of antisense
agents which have different chemical modifications that work through either enzymatic or steric
mechanisms to result in target gene inhibition. It was once believed that compounds that worked
via enzymatic RNase H mechanims were the most potent; however there is increasing evidence
that some of the newer generation antisense ODNs which work through steric hinderance are
equally potent (Grunweller, Wyszko, et al., 2003; Kurreck, Wyszko, et al., 2002).

First

generation structural modifications, such as phosphorothioate oligodeoxynucleotides (PSODNs), which have sulfur-substituted linkages, induce RNase H whereas other second and third
generation modifications such as phosphoramidates, phosphorodiamidate morpholinos, and
peptide nucleic acids (PNAs) do not (Wu, Lima, et al., 2004; Summerton, 1999; Gray, Basu, et
al., 1997). More recent analogues such as locked nucleic acids (LNAs) and small interfering
RNAs (siRNAs) have received attention due to their high efficacy (Obika, Hemamayi, et al.,
2001; Fire, Xu, et al., 1998).

Comparisons between LNAs, siRNAs and PS-ODNs found

siRNAs to be the most effective inhibitor of gene expression, but confirmed that PS-ODNs and
LNAs are less expensive, easier to handle, and have much greater stability in cell culture

24

compared to siRNAs, which have a half life of less than 2 hours in HeLa cells (Grunweller,
Wyszko, et al., 2003).

Similarly, comparative studies of siRNA and 2’-O-mehyoxyethyl

modified PS-ODNs targeting human Intracellular Adhesion Molecule-1 (ICAM-1) suggest that
siRNA and AS-ODN mechanisms may have comparable potencies, specificities, and duration of
effects, therefore demonstrating that while RNAi has generated a lot of excitement, AS-ODNs
are still a viable form of genetic therapy (Vickers, Koo, et al., 2003).
Although there have been many advancements made in their design and synthesis, antisense
therapeutics represent a less mature technology than small molecule pharmaceuticals. ISIS
Pharmaceutical’s cytomegalovirus prodrug, Vitravene, a second-generation phosphorothioate
ODN, is currently the only antisense drug with full FDA approval. Currently, a challenge to the
in vivo implementation of these techniques is the ability to control antisense activity, a problem
which could be overcome through targeted delivery to limit effects to cells and tissues of interest.
Common delivery techniques allow for receptor mediator targeting and have applications to
specific systems but may not work well outside of in vitro applications due to issues with
simultaneous effects in healthy and targeted cells. In order to limit antisense activity to specific
cell types in specific tissues or organs of interest, more precise targeting strategies have been
introduced which allow for the delivery of inactivated transgenes whose activity can be sitespecifically induced.
One such means of targeting antisense agents is through the control of hybridization.
Photoremovable protecting groups are chemical species that can be covalently attached to a
biomolecule via a photolabile bond and be used to suppress biochemical function (Kaplan,
Forbush, et al., 1978). These photocleavable “caged” species are designed to respond to a
specific wavelength of light such that, upon irradiation, the cage group is released and the
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biomolecule is liberated and its biological activity restored (McCray, Trentham, 1989). Caged
compounds are generally responsive to wavelengths in the 300-380 nm range of light
(Bernardinelli, 2005). Initial studies demonstrating the caging of biomolecules involved the use
of a nitrobenzyl derivative, 1-(2-nitrophenyl) ethyl (NPE), to inactivate ATP and subsequently
photorelease the ATP to its bioactive form by exposure to 340 nm light (Kaplan, Forbush, et al.,
1978).

More

recently,

a

similar

nitrobenzyl

derivitive,

1-(4,5-dimethoxy-2-

nitrophenyl)diazoethane (DMNPE), has been used to block genetic expression of plasmid DNA
(Monroe, McQuain, et al., 1999). Subsequent studies employed DMNPE in the cage inactivation
of nucleic acids as demonstrated in the reversible control of the hybridization ability of DNA
oligonucleotides and the ability to cage siRNAs

(Ghosn, Haselton, et al., 2005; Shah,

Rangarajan, et al., 2005).
Extending the application of caging chemistries to DNA ODNs with modified backbones
offers the potential of targeted control of antisense drug activity. This work demonstrates the
inhibition of antisense activity and the use of UVA light to restore its effects in cell culture. ISIS
2302 is a 20-mer phosphorothioate antisense oligodeoxynucleotide complementary to the 3’
untranslated region (UTR) of intercellular adhesion molecule-1 (ICAM-1/CD 54). Studies
evaluating the pharmacokinetics and effectiveness of ISIS 2302 have confirmed its ability to
suppress cytokine-inducible up-regulation of ICAM-1 in vitro (Yacyshyn, Barish, et al., 2002)
presumably through RNase H mechanisms (Stein, 2001; Walder, Walder, 1988). The influence
of the photocaging compound DMNPE on hybridization of ISIS 2302, a 20-mer PS ODN, was
modeled using a molecular beacon assay. Based on this model, a relationship between the
number of attached cage groups and the inactivation of hybridization activity was established. In
addition, the light-dose effects on cell morphology and ICAM-1 target protein expression were
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studied to determine that 40 J/cm2 of UVA light was the maximum dose that could be used for
photorestoration of antisense activity in cell based studies.

Caged ISIS 2302 activity was

controlled in HeLa cell cultures using this light and resulting ICAM-1 expression was measured
by flow cytometry.
Materials and Methods
ODN Caging and Purification
The PS ODN used was ISIS 2302, 5’-GCCCAAGCTGGCATCCGTCA-3’ (IDT,
Coralville, IA). PS ODN caging methods were adapted from previous studies by Ghosn et al.
(Ghosn, Haselton, et al., 2005). To activate the cage compound, 5 mg of 1-(4,5-dimethoxy-2nitrophenol) hydrazone (Molecular Probes, Invitrogen, Carlsbad, CA) was allowed to mix with
50 mg of manganese (IV) dioxide in 1 ml of dimethylforamaide (DMF) at 25 °C for 20 minutes.
The MnO2 was then filtered out using 100 mg of Celite supported by glass wool in a 1 cc
tuberculin syringe. Activated cage, 50, 100 or 150 µl, was then mixed with 200 µg of PS-ODN
in 80 µl of 50 mM Bis-Tris (pH 5.5), 120 µl water, and 50 µl DMF and agitated for 24 hours at 4
°C. Reactions were then removed from the agitator and microfuged for 30 seconds. A bed of
1500 µl of a 33% (v/v) DMF LH-20 Sephadex slurry (GE Healthcare, Piscataway, NJ) was
packed into a Mini Quick Spin column (Roche Diagnostics, Indianapolis, IN) through
centrifugation at 1000 x g, for 5 minutes (MiniSpin, Eppendorf, Westbury, NY). Excess cage
unassociated with PS-ODN was removed by filtering the 600 µl reaction volume through the
Sephadex column by spinning the column (1000 x g, 5 mintues). The caged product was then
further purified through the use of Microcon YM-3 (3000 molecular weight cut-off) filters
(Millipore, Bilerica, MA). Reactions were spun at 12 x 103 x g for 90 minutes, followed by a
400 µl water wash an additional spin for 120 minutes. Caged ODN was subsequently
resuspended in 70 µl water and stored at 4 °C, protected from light.
27

Determination of Caging Efficiency
In order to quantify the degree of DMNPE attachment, concentrations of native ODN and
DMNPE-caged ODN were compared through absorbance spectrophotometry. Samples were
scanned for absorbance from 230 to 500 nm (ThermoSpectronic Genesys 6, Waltham, MA).
DNA has a characteristic absorbance at 260 nm and no absorbance above 300 nm. DMNPE has
a characteristic 355 nm absorbance. Based on absorbance values efficiencies were calculated
using the following formulas adapted from Ghosn et al. (Ghosn, Haselton, et al., 2005):
A260 nm = [(εDNA/260)*(CDNA)*(l)] + [(εDMNPE/260)*(CDMNPE)*(l)]

(1)

A355 nm = [(εDMNPE/355)*(CDMNPE)*(l)]

(2)

Where A260 gives the absorbance at 260 nm; A355 is the absorbance of DMNPE at 355 nm; ε is
the molar extinction coefficient for each molecule at the specified wavelength; c is the
concentration of the solution; l is the path length of the cuvette (1 cm) and 19 is the total number
of phosphate groups in the ODN. Based on concentrations of DMNPE and DNA in each sample,
caging efficiencies were determined using the following equation:
Cageefficiency = [(CDMNPE ÷ CDNA) ÷ 19] * 100

(3)

Photoactivation and Fluoresence Hybridization Studies of Caged ODNs
In order to determine light doses necessary to release caged-ODNs, 0.5 µg native or caged
ODNs were exposed to 365 nm light for increasing durations of time. The UVA light source
used in these studies has a peak output at 365 nm and a fluence rate of 0.665 W/cm2 at 4.2 cm
(GreenSpot, American Ultraviolet, Lebannon, IN) when used in conjunction with short bandpass
(SWP-2502U-400; Lambda Research Optics, CA; diameter 25.4mm; 1.5mm thick) and IR (KG2; Lambda Research Optics, CA; 50.8mm square, 2mm thick) filters. Following light exposure,
ODNs were mixed with a molecular beacon, Molecular Beacon-1 (MB1; Biosearch
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Technologies, Novato, CA) that was specifically designed to hybridize to ISIS 2302 (Monroe,
2005). The sequence of MB1 is 5’-FAM-gtgcgTGACGGATGCCAGCTTGGGCcgcac-BHQ13’ where capital letters represent the bases complementary to ISIS 2302, lowercase letters
represent the self-complimenting bases forming the stem of the beacon structure, and the
underlined

sections

represent

the

fluorophore

([3’,6’-dipivaloylfluoresceinyl)-6-

carboxamidohexyl]-1-O-(2-cyanoethyl)-(N,N-diisopropyl)phosphoroamidite

(FAM))

and

quencher (Black Hole Quencher-1). Hybridization studies were done by mixing 450 ng of native,
caged, or caged-flashed ODN and 150 ng of MB1 (3:1 ODN:MB1 ratio) in 50 mM NaCl, 1 mM
EDTA (pH 7.0). Hybridization mixtures were denatured at 95 °C for 5 minutes and slowly
cooled over 20 minutes to a final temperature of 25 °C (iCycler, BioRad, Hercules, CA) .
Fluorescent analysis was carried out by exciting hybridization mixtures (100 µl) at 492 nm and
detecting emission at 515 nm using a LS55B Luminescence Spectrophotometer (Perkin Elmer,
Boston, MA).

Figure 2.1. Molecular beacon hybridization assay
Gel Electrophoresis: Comparison of Caging Among Different ODN Variations
Native, caged, and cage-flashed 20-mer ODN were compared by gel electrophoresis.

Two

phosphorothioate variations were used to demonstrate cage and cage-release effects on ODN
mobility: fully thioate linked and 5’-3’-end thioate linked. The ODNs were run on a 15%
polyacrylamide non-denaturing gel in tris-borate (TBE) buffer (100 mM tris-borate; 2 mM
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EDTA; pH 8) at 70 V for 105 minutes. Gels were then stained with 1X SYBR-Gold nucleic acid
gel stain (Molecular Probes, Eugene, OR) in TBE buffer for 20 minutes.
Cells and Culture Conditions
Human epithelial carcinoma (HeLa) cells were maintained in Dulbecco’s modified
Eagle’s reduced serum medium (DMEM-RS) supplemented with 3% fetal bovine serum (FBS)
(Hyclone, Thermo Scientific, Logan, UT). Cells were grown at 37° C in a 5% CO2 humidified
atmosphere and routinely split one to two times a week following trypsinization.

For lipid-

mediated transfection, cells were seeded at a density of 50,000 cells per well on 12-well plates
(BD Falcon, Franklin Lakes, NJ) and allowed to adhere for 18-24 hours. Cells were then washed
1x with pre-warmed (37° C) OptiMEM (Invitrogen, Carlsbad, CA). For each well, 0.26 µM AS
ODN was complexed at a 3:1 lipid:DNA ratio with 4.5 µl Oligofectamine transfection reagent
(Invitrogen, Carlsbad, CA) in 100 µl of OptiMEM for 15 minutes at room temperature.
Transfections were carried out in a total volume of 0.9 mL OptiMEM. Cells were incubated for
5 h at 37 ° C, 5% CO2 after which transfection media was replaced with 0.9 mL fresh OptiMEM
and appropriate wells were flashed. Medium was then replaced with 0.9 mL DMEM containing
3% FBS. After an additional 4 h incubation 100 U/mL IFNγ was added to appropriate wells to
stimulate ICAM-1 expression and cells were incubated overnight. Cells were then trypsinized
with 0.5 mL of 0.25% trypsin (Hyclone, Logan, UT) for 5 minutes at 37 ° C, 16 h after
stimulation with IFNγ.
Quantification of ICAM-1 Expression: Immunofluorescence and Flow Cytometry
Cells were washed 1x with CMF-PBS containing 2% Bovine Serum Albumin (BSA) (EBD
Biosciences, LaJolla, CA). Cells were then incubated for 30 minutes at room temperature with 5
µl of a phycoerytherin (PE)-conjugated or 2.5 µl of an Alexa Fluor 488 CD54/ICAM-1
monoclonal antibody (BD Biosciences, Franklin Lakes, NJ) with 20 µL 2%BSA in CMF-PBS.
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Cells were then washed 1x with 0.5 mL CMF-PBS and subsequently resuspended in CMF-PBS
containing 1% paraformaldehyde (pH 7).
Data acquisition was performed on a Becton-Dickinson FACScan flow cytometer employing
a 15mW 488 nm argon-ion laser and 530 nm (FITC) or 585 nm (PE) bandpass filter and
CellQuest Pro Software. For each sample, side scatter, forward scatter, and fluorescence data
(FL2 for 530 nm; FL3 for 585 nm) were collected for 20,000 cell events. Analysis was
performed using WinList software (Verity Software House, Topsham, ME). Dead cells were
gated out using forward versus size scatter dot plot data and the remaining live cell population
was further gated based on IFNγ negative controls using FL2 vs. FL3 fluorescence dot plots.
Antisense effects were quantified as number of responsive cells based on the percentages of cells
in the IFNγ negative control gate. In addition, ICAM-1 expression was quantified based on the
linearized mean fluorescence intensity (mFI). Protein expression levels were standardized using
the following formula adapted from Nedbal et al (Nedbal, Tomakidi, et al., 2002):
Percent Knockdown = [(mFI ASODN+/IFNγ+)-(mFIIFNγ-)] / [(mFI IFNγ+)– (mFIIFNγ-)]

(4)

UVA Light Effects on ICAM Expression
The target gene ICAM-1 is expressed at low basal levels in the absence of any stimulatory
cytokine. To validate our system we tested the effects of 365 nm light on both basal level and
IFNγ-stimulated ICAM-1 protein expression. Triplicate samples of pre- or post-transfected cells
were exposed to 10, 20, 40, 80, 120, or 200 J/cm2 of light were performed in. Cells were
analyzed for ICAM-1 expression, as described, using flow cytometry.
Results
Non-Denaturing Gel Electrophoresis of Caged ODNs
In order to compare the effects of both caging and photo-release on the AS ODN, gel
mobilities were assessed by non-denaturing gel electrophoresis. For two AS ODN variations,
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fully phosphorothioate modified ODN and 5’3’-end phosphorothioate modified ODN, native,
caged, and cage-flashed samples were compared. Band intensities are higher for each native
sample (Figure 2.2; lanes 2, and 5) as compared to the corresponding cage and cage-flashed
1

20 base pair ladder

2

Native PS ODN

3

Caged PS ODN

4

Cage-Flashed PS ODN

5

Caged Bands
Native 5’3’-end modified PS ODN

6

Caged 5’3’-end modified PS ODN

7

Cage-Flashed5’3’-end modified PS ODN

Figure 2.2. Non-denaturing gel with 50 ng native, caged, and caged-flashed ODNs

samples (Figure 2.2; lanes 3, 4 and 6, 7, respectively). The differences in intensities between
cage and native samples is not unexpected due to the potential interference of the attached cage
group in the ability of the SYBR-Gold
stain to intercalculate between the
bases.

The limited increase in

intensity of caged-flashed bands as
compared

to

demonstrates

the

caged

incomplete

bands
photo-

removal of the cage groups from the
Figure 2.3. Absorbance spectra of caged and cageflashed ODN
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Figure 2.3. Absorbance spectra of caged and cagedflashed ODN

ODNs after exposure to 40 J/cm2.
However,

at

least

a

partial

photorelease of the ODNs from cage groups is suggested by the characteristic electrophoretic
mobility shifts corresponding to the changes in DMNPE attachment. Cage-flashed bands have
increased mobility over cage bands approaching that of the native sample bands. Band shifts
correlate with absorbance spectrophotometry results (Figure 2.3) which show a significant
decrease in the 355 nm peak after flashing, resulting in a cage-flashed product whose absorbance
characteristics also more closely resemble native ODN.
Fluorescent Measurements of Hybridization Products
The fluorescence of MB1 indicates hybridization with its a complementary target. MB1
solutions with either native or caged-flashed ODNs resulted in fluorescent measurements that
were significantly higher than solutions of MB1 alone or of MB1 with caged ODN (Figure 2.4).
MB1 alone in solution exhibits very little background fluorescence as demonstrated by an
average reading of 114 ± 2.5 (mean ± SEM, n=3) relative fluorescence units (RFUs). By
comparison, when MB1 was mixed with the target ODN, hybridization resulted in readings of
848 ± 6.2 (n=4) RFUs.

Caged ODNs were also hybridized to MB1 and fluorescence

measurements were found to be dependent on the number of attached cage groups, but were
always less than native ODN hybridization mixtures. Three different amounts of cage (1.08mM,
4.32mM, or 6.48mM) were reacted with ODNs having fully phosphorothioate backbone
chemistry. In addition, two different amounts (2.16mM and 6.48mM) were tested in two other
backbone chemistries, an ODN with three phosphorothioate modifications at each (3’ and 5’)
end, and an ODN with alternating phosphorothioate and phosphodiester backbone chemistry. In
order to identify what effect, if any, phosphorothioate chemistry had on cage group attachment
and release abilities, a comparison was done between the three phosphorothioate chemistries
with 6.48 mM of DMNPE. The amount of light used to photoactivate the caged effector ODN
(40 J/cm2) was based on cell light dose tolerance limits (data follows). Using this light dose
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Figure 2.4. The effects of different amounts of DMNPE on hybridization
activity inhibition and photorestoration. Full phosphorothioate backbone
chemistries were evaluated for hybridization with a complementary molecular
beacon at low (1.08mM), medium (4.32mM), and a high (6.48mM) cage
concentrations. Other phosphorothioate modifications were initially tested at a
mid-range (2.16mM) and high (6.48mM) concentrations. Cage-flashed samples
were dosed with 40 J/cm2 of light.
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100% photoresoration was not seen in any of the caged samples. An alternative method would
have involved increasing light doses until maximum photo-release was achieved. However, as
this system was being evaluated for in vitro use, total light doses were set below cellular
thresholds. The minimum degree of caging needed to block bioactivity was then evaluated so
that minimal light doses could be used for photoactivation.
Table 2.1. Relative effects of cage on fluorescence emission and hybridization
activity between samples. Sample RFU values represent total RFU with basal
molecular beacon RFU (114) subtracted out. Hybridization activity was
calculated as a percentage of native activity, 848 ± 6.2; n=4 (mean ± SEM) RFUs
Caging
Caged
Cage-Flashed
mM
Cage Efficiency RFU % Activity RFU % Activity
13%
538
63
633
75
1.08
PS
41%
32
4
295
35
4.32
82%
0
0
28
3
6.48
20.8%
312
37
525
62
2.16
5'3' Modified PS
20.4%
0
0
22
3
6.48
70%
396
47
656
77
Alternating PS
2.16
Modification
73%
2
0
75
9
6.48
For all phosphorothioate chemistries tested, reactions that received higher amounts of cage
compound exhibited lower relative fluorescence, indicating a lower level of hybridization ability.
For heavily caged (6.48 mM) reactions the addition of 150 µg of DMNPE to 200 µg ODN
resulted in complete hybridization inactivation. By comparison, only reacting 25 µg of DMNPE
with 200 µg ODN (1.08 mM reactions) allowed the ODNs to maintain 63% of their activity. In
order to better characterize the relationship between cage presence and hybridization activation,
we evaluated the relationship between the degree of cage attachment and hybridization
inactivation in the fully phosphorothioated ODN (Figure 2.5). This relationship was modeled
with a sigmoidal dose-response as a function of the number of attached cage groups using
SigmaPlot 9 software (SYSTAT, San Jose, CA).
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Approximate Number of Attached Cage Groups per 20 mer PS ODN
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Figure 2.5. The relationship between degree of PS ODN caging and the
blockade of hybridization ability

y = 97.1 / (1+ exp ( - ( x – 15.9) / - 4.75 ))

(5)

Col 1 vs Col 2
Col 4 vs Col 5
R2 = 0.975
x column vs y column

Molecular beacon assays allowed for the monitoring of hybridization abilities of ODNs at
95°C in a thermal cycler. In order to confirm that antisense ODNs would also hybridize to their
targets in vitro, a series of molecular beacon hybridization assays were conducted to compare
activity at 95°C and 37°C. Various concentrations of ODNs (90-875 ng), as an estimate range of
in vitro target availability, were mixed with molecular beacon.

Each set of reactions was

conducted over a 20 minute hybridization period, either in the thermal cyler at 95°C or in the

36

incubator at 37°C. Hybridization did occur at each temperature, indicating in vitro hybridization
ability. Based on these results 450 ng of DNA were used in subsequent hybridization assays.

Figure 2.6. Hybridization temperature comparison of molecular
beacon activity
Effects of UVA Light on ICAM-1 Expression in HeLa Cells
Determination of the required light to photorelease caged AS ODNs in vitro must also
account for the ability of the cells to withstand photo-treatment. To account for experimental
condition effects on cells, HeLa cell responses to UVA light were measured under control
(cytokine-stimulated) and experimental (AS transfected) conditions. Light doses below 40 J/cm2
had negligible effects on ICAM-1 expression in either controls or antisense transfected cell
populations. Doses above 40 J/cm2 resulted in a 42.2 ± 4.7% (mean ± SEM; n=3) decrease in
ICAM-1 expression in positive controls and a 28.4 ± 2.8% (mean ± SEM; n=3) decrease in
antisense treated cells (Figure 2.7 (a)). For all cell experiments, each “n” replicate represents the
analysis of 20,000 cell events. In addition to changes in protein expression in response to light
treatments, morphological changes were also monitored. Cell morphology remained relatively
unchanged at doses below 40 J/cm2 but alterations became increasingly evident as light doses
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(a)

*

*

(b)

Figure 2.7. Effects of UVA light on HeLa Cells (a) Effect of UVA light doses on
ICAM-1 expression (mean ± SEM) as measured by flow cytometry in cytokine upregulated cells in antisense treatments and controls. Light doses below 40 J/cm2
were not significantly different (t-test p<0.05; n=3) between controls or between
antisense treatments. Statistically different treatments are marked with asterisks. (b)
Cell morphology of controls cells in response to light dose treatments
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increased (Figure 2.7 (b)). The 60s (40 J/cm2) dose had little effect on number of attachedc cells
whereas doses of 180s and 300s resulted in loss of adherent cells.
Effects of Transfection Lipids on ICAM-1 Expression in HeLa Cells
In order to verify that changes in ICAM-1 protein expression were a result of up-regulation
and knockdown alone and not due to lipid effects, we compared basal and IFNγ-stimulated
controls with or without exposure to lipid transfection reagent complexed to a control ODN. The
control sequence used in these studies was ISIS 8424, a 20-mer phosphorothioate ODN
composed of a scrambled sequence of the same base composition as ISIS 2302. This sequence
has been previously shown to have no biological target (Mehta, Stecker, et al., 2000). Results
demonstrate that transfection conditions did not exhibit any effect on ICAM-1 protein expression
at the concentrations used (Figure 2.8). There was no significant difference between basal

Figure 2.8. Effects of Oligofectamine on HeLa cell expression of ICAM-1
Linearized mean fluorescence intensity of ICAM-1 expression is nonsignificantly affected by the presence of the lipid (t-test p<0.05; n=3)
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ICAM-1 expression in untreated cells and cells exposed to Oligofectamine. Similarly, there was
no significant change in IFNγ induced expression with Oligofectamine treatment (t-test, p<0.05).
Cellular Delivery of Native and Caged ODNs
Several cationic lipids have been successfully used for the delivery of ODNs to various cell
types. In order to determine which lipid worked the best with this system, two of the most
commonly used lipids, Oligofectamine and GenePorter (Genelantis, San Diego, CA) were
compared. Lipids were complexed with a 20-mer randomized phosphorothioate sequence with a
5’FAM label (TriLink, San Diego, CA) to analyze cell delivery. Oligofectamine was
significantly

more

efficient than GenePorter
for the delivery of 20-mer
phosphorothioate ODNs
to

HeLa

p<0.05;

cells

(t-test

n=3)

(Figure

20-mer

FAM-

2.9).
The

labeled ODN sequence
was

also

used

to

determine whether or not
the attached cage group
had any effect of the
ability
conjugate

of

lipids
to

to

ODNs.

Figure 2.9. Comparison of lipid delivery agents
Oligofectamine or GenePorter lipids were conjugated with 1µg of
a 20-mer random phosphorothioate sequence with a 5’FAM label.
Lipid complexes were found to have statistically significant
differences in the delivery of ODNs to HeLa cells (t-test p<0.05;
n=3) Each “n” replicate represents 20,000 cell events.
Oligofectamine demonstrated more significant transfection ability
based on flow cytometry analysis.

Cells were transfected with 1.5 µg of either caged or native FAM-labeled ODNs complexed to
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Oligofectamine. Flow cytometric analysis determined that there was no significant difference in
the ability of Oligofectamine to transport either caged or native PS ODNs (t-test p<0.05; n=3)
(Figure 2.10).

Figure 2.10. Confirmation of lipid-mediated transfection of caged
and native ODNs Oligofectamine showed no statistical differences in
ability to complex to either native or caged 20-mer randomized
phosphorothioate ODNs with 5’FAM labels (t-test p<0.05; n=3)
Knockdown of ICAM-1 Expression in HeLa cells
Experiments were conducted to determine differences in ICAM-1 expression between cells
treated with native or caged antisense before and after photo-release. In this analysis, PEconjugated monoclonal antibodies were used to label ICAM-1 proteins. Fluorescence dot plots,
FL3 vs. FL5, of native, caged, and cage-flashed antisense treatments were compared to IFNγ
positive and negative controls as an indication of gene knockdown (Figure 2.11). In HeLa cells
transfected with 1.5 µg of AS ODN, ICAM-1 expression in 78 ± 0.03% of whole cell
populations were not up-regulated in response to IFNγ stimulation. Comparatively, only 9.5 ±
1.33% of cells remained unaffected in IFNγ-stimulated in controls (mean ± SEM) (Figure 2.12).
Cell samples transfected with caged antisense had reduced antisense activity evidenced by
decreases in the number of cells experiencing ICAM-1 knockdown. These samples had reduced
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Antisense
(knockdown) control

Positive
(up-regulated) control

Cage (1.1mM) Antisense

Flashed
Cage (1.1mM) Antisense

Cage (4.32mM) Antisense

Flashed
Cage (4.32mM) Antisense

Cage (6.48mM) Antisense

Flashed
Cage (6.48mM) Antisense

FL3
Figure 2.11. Effects of cage and cage-flashed antisense ODNs on ICAM-1 expression in
HeLa cells. Each graph represents 20,000 cell events analyzed by flow cytometry.
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ICAM-1 expression in 66±1.15%, 25±1%, and 25.3±8% (mean±SEM) of total cell populations
with 1.08 mM, 4.32 mM, and 6.48 mM DMNPE, respectively (Figure 2.12). Cage-flashed
samples were transfected with caged antisense that were subsequently photo-released through
exposure to 40 J/cm2 of 365 nm light. These treatments had increased antisense activity over
caged samples, approximately equal to 12%, 31.6%, and 6.3% increases in percentages of cells
with ICAM-1 knockdown. These results correlate with hybridization studies that indicated





‡


Figure 2.12. Effects of antisense treatments on knockdown of ICAM-1 protein expression
Mean percentage of cells in knockdown region ± SEM. Asterisks () indicate significant
differences in photo-restoration activity from caged samples at equivalent DMNPE
concentrations. Statistical differences between IFNγ-stimulated controls and caged antisense
treatments are indicated (). Statistical differences between antisense activity and photorestored (cage-flashed) activity are also shown (‡). Student’s t-test were used with p<0.05
considered significant with n=3 replicates, each “n” replicate representing 20,000 cell events.
reactions with smaller quantities of cage had more system “leak” where caged ODNs retained
larger percentages of antisense activity (Figures 2.12, 2.5). Reactions with the largest amount of
cage (6.48mM) showed no significant difference in the number of cells affected by antisense
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activity from IFNγ-stimulated controls (t-test p<0.05) (Figure 2.12). This also correlates with
hybridization data, which showed that reactions with 6.48mM cage had no hybridization activity
with the antisense target (Figures 2.12, 2.4).
In addition to comparing the number of cells affected, mean linear fluorescence intensity
(mFI) for all cell events was also used as an indication of protein expression in flow cytometry
analysis. Fluorescence intensities of antisense treatments indicated a knockdown of protein
expression from 277.5 ± 10.1 in IFNγ-stimulated controls to 44.54 ± 1.26 (mean ± SEM) (Table
2.2).

Cells transfected with caged antisense, 1.08 mM, 4.32 mM, or 6.48 mM, displayed

antisense activities that were 40 ± 3%, 97 ± 5%, and 88 ± 7% of IFNγ-stimulated controls,
respectively. Of these, only the 1.08 mM caged antisense treatment was significantly different
from the stimulated control (t-test p<0.05). The mFI’s of all caged-flashed treatments showed
significant differences from the mFI of antisense samples (t-test p<0.05). Protein expression in
cage-flashed samples decreased from caged samples by 24 ± 7%, 40 ± 15%, and 13 ± 2% for
Table 2.2 . Relative effects of cage and caged-flashed ODNs on mean linear fluorescence
intensities. Fluorescent intensity relates to the stimulated expression of ICAM-1 protein as
measured by flow cytometry.
(mean ± SEM).
Mean
Fluorescence Statistical
Treatment
Intensity
Significance
IFNγ-Stimulated Control
277.5 ± 10.1
Antisense (AS)
44.54 ± 1.26
1.08mM Caged AS
112.4 ± 4.1

1.08mM Cage Flashed AS
83.8 ± 6
‡
4.32mM Caged AS
272.2 ± 22.6
4.32mM Cage Flashed AS
157 ± 24.1
‡
6.48mM Caged AS
244.8 ± 25.2
6.48mM Caged Flashed AS
213.5 ± 18.7
‡
Asterisks () indicate significant differences in photo-restoration activity from caged
samples at equivalent DMNPE concentrations. Statistical differences between IFNγstimulated controls and caged antisense treatments are indicated (). Statistical differences
between antisense activity and photo-restored (cage-flashed) activity are also shown (‡).
Student’s t-test was used with p<0.05 considered significant with n=3 replicates, each “n”
replicate representing 20,000 cell events.
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1.08 mM, 4.32 mM, and 6.48 mM treatments, respectively. None of these decreases were
statistically significant (t-test p<0.05).
In summary, cell study results confirm hybridization study conclusions that there is a balance
between maximum cage inactivation and maximum amount of photorestoration of antisense
activity. In both the low (1.08 mM) and high (6.48 mM) cage reactions, we see the extremes of
caging efficiency where knockdown (1.08 mM) or photorestoration (6.48 mM) are minimal.
However, at the midpoint, we see a 53% reduction in the percentage of cell population affected
by antisense activity and a photo-recovery of antisense activity to within 21.6% of the native
antisense control (Figure 2.12).
Discussion
Our results indicate that photoremovable protecting groups can be covalently linked to a
phosphorothioated AS ODN and introduced into cell culture as a means of controlling antisense
effects on gene expression. We have demonstrated the ability of a specific cage group, DMNPE,
to reduce hybridization ability of phosphorothioate DNA. This ability to influence hybridization
activity as measured by molecular beacon assays was previously demonstrated with
phosphodiester DNA using the same cage group (Ghosn, Haselton, et al., 2005). This work
found that the ability of phosphorothioate antisense DNA to achieve gene knockdown varied
based on the number of associated cage groups. This trend was evidenced through hybridization
assays as well as flow cytometry analyses of in vitro studies. This points out one of the
limitations to the employment of any cage compound in genetic therapy. The problem of system
“leak” occurs when too few cage moieties are attached to the effector molecule thus allowing
activity to occur in the un-induced state. However, excessive caging may make achieving
complete photorestoration difficult. Increasing the dosage of light applied to the system could
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potentially lead to greater photorestoration of antisense activity in a larger percentage of the cell
population. Another potential way to circumvent this issue would be to photorelease the ODNs
prior to transfection.

This “pre-flashing” method was previously demonstrated in studies

involving the cage control of plasmid activity in HeLa cells (Monroe, McQuain, et al., 1999).
However, although results from that study indicated an increase in photo-restored transgene
expression, 100% photo-restoration was still not achieved (Monroe, McQuain, et al., 1999).
The solution to this problem lies in finding a balance between the minimum number of cage
groups necessary to inactivate ODNs and the maximum number of cage groups that can be added
before photoreactivation is too difficult to achieve. Based on molecular beacon assays we found
that the attachment of a specific number of cage groups results in a predictable blockade of
hybridization inactivation as modeled by equation 5. The attachment of 2-16 cage moieties per
20-mer ODN resulted in some degree hybridization inactivation. However, only about 8 cage
groups (4.32 mM cage) per ODN were necessary to achieve 96% inhibition of hybridization
activity.
Although hybridization inhibition required the attachment of a minimum number of cage
groups, the maximum number of attached cage groups that would allow for significant
photorestoration within cell light-dose tolerance limits needed to be determined. Studies were
done to determine the upper limit of light doses tolerated by HeLa cells so that these limitations
could be used to optimize caging conditions within these constraints. In the evaluation of the
effects of 365 nm light on inducible ICAM-1 expression in HeLa cell culture, we compared light
doses to minimize cytotoxicity due to photoexposure and maximize the amount photoactivating
light available to cage inactivated ODNs. Based upon light-dose results, we determined the
maximum dose tolerated by cells before adverse effects on cell viability and immune response
were observed to be 40 J/cm2.

Molecular beacon assays found that at least partial
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photoresoration of bioactivity was achieved with each caged ODN (1.08 mM, 4.32 mM, and 6.48
mM) studied. The largest shift in cage and cage-flashed activity was seen with the attachment of
8 cage groups (4.32mM cage) which demonstrated a 35% increase in hybridization activity upon
exposure to 40 J/cm2 of 365 nm light.
Molecular beacon hybridization results were confirmed with flow cytometric cell based
assays. The 96% inhibition of antisense activity achieved with 4.32 mM of cage corresponded to
inhibition of antisense activity in vitro such that only 25 ± 1% (mean ± SEM) of cell populations
showed any antisense response with this same ODN. This corresponded to a 97 ± 5% retention
of interferon-stimulated ICAM-1 activity in vitro based on mFI protein expression analysis.
Associated photoresoration of hybridization activity in vitro upon exposure to 365 nm light
resulted in 40 ± 15% decrease of ICAM-1 expression in 56.7 ± 5.9% of the cell population.
These results show that antisense agents have the ability to significantly reduce target gene
expression, but that they do not afford 100% control over biological systems. In addition, these
results show that cage compounds can be used to reversibly control the effects antisense agents
have on gene expression. Though similarly, caging chemistry control over antisense biological
effects is also not 100%. This study does, however, show that the degree of control can be
maximized through the optimization of caging reaction conditions.
The use of chemical cages in the control of hybridization ability as a targeted delivery
strategy was tested though the delivery of DMNPE-inactivated antisense agents to HeLa cells
that were subsequently activated with near-UV light. This research design was modeled after a
system first introduced by Bennett et al and modified by Monroe et al, involving the monitoring
of protein production in HeLa cell cultures via a cytokine inducible anti-ICAM-1 directed
antisense system (Bennett, Condon, et al., 1994; Monroe, 2005). It is possible that the efficiency
of cage release ability within HeLa cells may be improved through the implementation of a
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different cage moiety. In addition to nitrobenzyl derivatives, there are a number of other cage
group chemistries that have been used in the inactivation of a variety of biomolecules including
carboxylic acids, calcium, and ATP (Shembekar, 2005; Bernardinelli, Haeberli, et al., 2005;
Aarhus, Gee, et al., 1995) as well as in controlling the bioactivity of nucleobases, DNA, RNA,
and modified ODN versions (Iwase, Kitani, et al., 2003; Shah, Rangarajan, et al., 2005; Heckel,
Mayer, 2005; Ando, 2001). Many of these newer cage groups have been thought to offer
improved photochemical characteristics over the slow photolysis rates and low quantium yields
observed with DMNPE-ATP (Wooton, 1989). However, more recent experiments involving
caged NAD, NADP and the antibiotic doxycycline have indicated that DMNPE release rates and
product formation may have better photochemical characteristics than what was once thought,
indicating that these characteristics may simply be dependent upon the moiety being caged
(Cohen, Stoddard, et al., 1997; Cambridge, Geissler, et al., 2006).
Given the recent success with DNA (Ghosn, Haselton, et al., 2005; Tang, Dmochowski, 2005)
cage compounds may provide the answer to overcoming targeting issues with antisense
therapies. The first and only antisense drug to have been granted FDA approval is Vitravene
(formivirsen sodium), a phosphorothioate agent that is delivered via direct ocular injection and
thus has restricted access to systemic circulation (de Smet, Meenken, et al., 1999; Crooke, 1998).
Intended target sites of other antisense agents may not be as easily accessible as the retina and
may necessarily rely on systemic delivery to reach target tissue. For instance, one of the more
recent antisense therapeutics being developed, Alicaforsen (ISIS 2302) is the first to target a
gastrointestinal (GI) disease (Caprilli, Viscido, et al., 2002). With the DMNPE caging group, we
were able to deliver cage-inactivated ISIS 2302 to HeLa cells and administer targeted doses of
light that resulted in the in vitro activation with no quantifiable negative effects on cell
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population. This work demonstrates how cage chemistries might help to restrict activity of
antisense agents, such as ISIS 2302, to optically available target tissues in disease treatment.
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CHAPTER III
CONCLUSIONS AND FUTURE CONSIDERATIONS
Conclusions
The use of antisense strategies is a very promising field of gene therapy. To date, there are
several antisense drugs that have undergone or are in stage 3 clinical trials for FDA approval.
One of the main areas of interest in the development of these therapeutics is how to control and
target both their in vitro and in vivo effects to only cells and tissues of interest. Photocleavable
cage molecules have been used towards this goal of achieving the spatial and temporal control of
phosphodiester nucleic acids (Ghosn, Haselton, et al., 2005). This work demonstrated the ability
to spatially- and temporally- control the effects of phosphorothioate antisense activity with
photocleavable cage compounds in vitro.

In this way, nucleic acids therapeutics could be

delivered to cells in inactive form and be induced for biological activity with light exposure.
Few studies have been done to date attempting the photo-control of gene expression in cell or
animal systems, and of those studies, none were able to demonstrate a relationship between
degree of inactivation and degree of photorestoration (Monroe, McQuain, et al., 1999; Ando,
2001; Shah, Rangarajan, et al., 2005). We have shown that the covalent attachment of caging
groups to a phosphorothioate ODN inhibits hybridization ability and that release of the cage
groups through photo-triggering with near-UV light results in hybridization reactivation. We
have also shown that there are a minimal number of cage groups required to achieve inactivation
and that this is balanced by a limit to the maximum number of cage groups that can be attached
and released to result in photorestoration of bioactivity. In addition, we were able to introduce
these biologically inactive, caged ODNs into cells and, upon exposure near-UV light, we were
able to generate inhibition of target protein expression levels.
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Antisense ODN inactivation was achieved through what has been referred to as a ‘statistical’
method of caging, in which a cage groups are nonspecifically attached to the DNA structure.
Attachment of the cage compound 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane (DMNPE) was
assessed through spectrophotometry and gel electrophoresis and inhibition of activity was
confirmed

via

a

spectrophotometry.

molecular

beacon

hybridization

assay

analyzed

by

fluorescence

Caged ODNs are unable to hybridize to the molecular beacon target,

resulting in a lack of fluorescence as compared to native ODNs which are capable of fully
hybridizing to the molecular beacon target. Several variations on the amount of cage were
reacted with native ODNs and tested in an effort to find the minimal number of attached cage
groups that resulted in maximal inactivation of the native species while allowing for
photorestoration to be achieved within cell light dose tolerance limits. Our results indicated an
average of 41 % caging efficiency, corresponding to the association of 8 cage moieties,
decreased hybridization ability by 96% and exposure to 365 nm light restored 35% of
hybridization activity.
In addition, in vitro studies of this system were analyzed through the assessment of target
protein expression levels using flow cytometry. Results revealed that caged ODNs only affected
protein expression levels in 25% of cell populations. Subsequent irradiation with 40 J/cm2 of 365
nm light resulted in restoration of bioactivity as evidenced by the increase in percentage of cells
affected to 56.7%. This indicates that it is possible to achieve targeted delivery of antisense
agent to cell systems with some control of bioactivity. Our results also show that targeted
photoactivation of caged ODNs can be achieved with light doses that impart little to no cell
toxicity.
In conclusion, we have shown that cage compounds can be used to achieve spatio-temporal
control of hybridization ability and protein synthesis in vitro through photocleavage mechanisms.
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This work demonstrates a potential solution to achieving the systemic delivery of antisense drugs
through the development of laboratory strategies to better study their reaction mechanisms and
kinetics. Current approaches that rely on more direct means of antisense delivery, such as direct
tissue injections or oral delivery techniques, have variable, and usually very low, delivery
success (Jaaskelainen, 2002).
Future Directions
Despite the success achieved in this study with the use of the DMNPE caging compound,
there are numerous alternative cage groups that have been developed in recent years, which may
be more appealing in certain applications. The most significant issue with DMNPE is its
relatively low quantum yield, a characteristic that is intensified through the addition of the sulfur
modifications on the DNA backbone (Walker, Reid, et al., 1988). The development of cage
groups with higher quantum yields will allow for more rapid photolysis at longer wavelengths,
which will be easier for living tissue to tolerate.

Recently, a 7-N,N-diethylamino-4-

hydroxymethyl coumarin cage group conjugated to a carboxylic acid was shown to have a
quantum yield of 0.11 when photolysed with a 10 ns pulse at wavelengths greater than 400 nm
(Shembekar, 2005). This exceeds the quantum yields of 0.09 that have been been calculated for
DMNPE-caged ODNs (Ghosn, Haselton, et al., 2005). In addition, quantum yields of visible
light responsive groups have the potential to be significantly enhanced through two-photon
excitation (Denk, Strickler, et al, 1990). Ultimately, the achievement of caged ODNs with a
visible, longer and deeper penetrating, wavelength responsive group will eliminate most of the
concern with cytotoxic light effects, especially when coupled with TPE systems which will allow
for these lower energy photons to combine their effects to accomplish rapid photolysis.
Overall, caging efficiencies achieved with any cage group, regardless of the photoresponsive
wavelength, will be greatly enhanced by the ability to achieve site-specific placement of a
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specific number of cage moieties to a DNA molecule. The methods employed in these studies
were ‘statisical’ or relatively randomized caging conditions in which variations of reaction
conditions resulting in a range of caging efficiencies were compared for optimization. The
ability to cage targets on the backbone to achieve very specific and reproducible caging
efficiencies will allow for overall optimization on a much larger scale. However, there is a great
deal of difficulty in reaching that goal unless there is a clear understanding of the mechanism
involved, specifically on where the cage attaches. It was originally theorized that caging took
place along the negative backbone of the DNA molecule, a theory supported by the increased
affinity of the cage group for the more negatively charged phosphorothioate backbone (Monroe,
McQuain, et al., 1999; Ghosn, Haselton, et al., 2005). However, this may not necessarily be the
case. To be certain, the most reliable means of single site-specific cage incorporation is to
incorporate a photolabile cage during solid-phase synthesis. Unfortunately, this gives rise to a
number of other potential complications, as exemplified in a study be Iwase et al where a single
nitroveratryloxycarbonyl (NVOC) cage that was incorporated onto a thymine required 5 hours,
the equivalent to 61.2 J/cm2, of 355 nm light to uncage (Iwase, Kitani, et al., 2003). Similarly, in
a recent work by Krock et al, variations of 2-nitrobenzyl and 2-nitrophenyl ethyl groups were
shown to be capable of complete blockage of the activity of phosphoramidites (Krock, 2005).
The cage groups used were responsive to slightly longer (366 nm) wavelengths but showed very
slow release kinetics.
Comparisons between light, medium, and heavily caged solutions demonstrated that residual
active ODN present in less heavily caged samples results in system “leak” where uncaged ODNs
still exhibit hybridization ability. In order to address the problem of system leak, affinity
chromatography methods could be employed to separate native from caged ODNs. It has been
shown that nucleic acids can be fractionated on hydroxyapatite (HA) columns based on
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interactions between the negative charges on the DNA backbone and the positive charges in the
calcium ions composing the crystalline structure of the HA (Bernardi, 1965). Both singlestranded and double-stranded DNA can be adsorbed onto HA columns with a low (0.005-0.01
M) sodium phosphate buffer but desorption will be fractionated based on differences in their
affinities for increasing molarities of phosphate buffer over their affinities for the column
(Bernardi, 1965; Ahnstrom, Erixon, 1981). The affinities of several types of DNA for HA were
studied and it was found that DNA which demonstrates lower electrophoretic mobility has
corresponding lower binding affinity to HA (Bernardi, 1965). Therefore, as caged ODNs have
also demonstrated decreased electrophoretic mobility than native ODNs, presumably due to
phosphate alkylation, HA columns could be used as a means of purifying caged product by
fractionating it out from the mixed reaction product.
In addition to cage group considerations, it is also essential to perform a thorough analysis of
delivery systems to find the optimum transport mechanism for a specific application. Though in
this study, comparisons between two different lipid formulations, GenePorter (Genelantis,
Sandiego, CA) and Oligofectamine (Invitrogen, Carlsbad, CA), were done to determine the best
carrier for the native ODNs. For more in-depth analysis, the OliGreen Assay has been used to
evaluate the interactions between lipid carriers and different DNA structures (Sundaram,
Viriyayuthakorn, et al., 2005). The OliGreen dye fluoresces when bound to single-stranded,
non-lipid associated DNA ODNs and is unable to conjugate to lipid alone or lipid-ODN
lipoplexes (Gray, Basu, et al., 1997). Therefore, in order to identify the lipid that best associates
with caged ODN, the OliGreen assay could be employed to achieve more optimal cell delivery of
the asODNs used in this study.
Despite peaked interest in newer antisense agents such as morpholinos and PNAs, there
remain a number of advantages to phosphorothioate ODNs. Over the past decade, numerous
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studies have compared several ODNs types in an effort to determine the superior for antisense
treatments (Baker, Lot, et al., 1997; Yoo, Bochkareva, et al., 2004; Grunweller, Wyszko, et al.,
2003). Of these studies, those that actually performed analysis in cell systems typically used
only one or two delivery methods to compare all of the ODNs. From our own studies, we have
seen vast differences between transfection ability of a number of different cationic lipid reagents
in a single cell type. Similarly, we expect that different ODN chemistries will have differing
optimal delivery mechanisms. Studies such as the research conducted by Sazani et al, have
pointed out the ineffectiveness of naked and scrape-loading delivery methods for the transfection
of phosphorothioates (Sazani, 2001). Though the feasibility of delivery via conjugation to a
cationic lipid was also explored, the results may have been more positive had a thorough
comparison and evaluation of several cationic lipid variations been conducted (Sazani, Kang, et
al., 2001). Although some comparisons have been made among various lipid formulations to
determine which carrier type improves cellular delivery of AS ODNs, again results of such
studies are likely to vary based on ODN formulation, cell type, and the emergence of newer
lipids and have not taken into consideration nonspecific accumulations of AS ODNs within
cellular compartments (Ruponen, Yla-Herttuala, et al., 1999).
Finally, in addition to monitoring cell target protein levels, a complete analysis of antisense
effects in this system requires direct evaluation of the ability of the asODN to inhibit mRNA
synthesis. Reverse transcription polymerase chain reaction (RT-PCR) studies will allow for the
quantification of target mRNA levels and allow us to draw correlations between the control of
translation and protein expression. In addition, both protein and mRNA level results obtained
through the flow cytometry methods used herein and RT-PCR methods could be verified through
western and northern blotting methods, respectively, as a less quantitative confirmation of
results. However, the results herein demonstrate a promising step towards one of the idealized
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goals of cell and tissue engineering, which is to be able to achieve targeted delivery and
activation of antisense therapeutics only in cells and tissue of interest.
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APPENDIX: RAW CELL DATA
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92.90
57.80
63.20

std. dev.
14.52
23.27
17.06
8.55
8.05
8.31

1.5 ug
AS

std. error
10.27
16.45
9.85
4.94
4.65
4.80
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Time
0
15
30
60
180
300

time
(s)
0
0
0
15
15
15
30
30
30
60
60
60
180
180
180
300
300
300

lin mean
(of 98%)
70.2
66.12
59.35
65.27
68.56
66.67
73.06
68.54
66.59
67.95
70.36
58.65
27
18.4
18.9
48.62
14.94
31

Averages
51.89
52.41
56.07
52.32
12.10
22.19

# of cells
20000
20000
20000
20000
20000
20000
20000
20000
20000
20000
20000
20000
20000
6780
11319
3180
20000
20000

Normalized
46.20
46.70
49.90
46.60
18.20
33.30

std. dev.
5.48
0.81
3.32
6.18
4.83
16.85

std. error
3.16
0.47
1.92
3.57
2.79
9.73

Figure 2.12:

n=1
n=2
n=3
average
std. dev.
sqrt n=3
std. error

Pos Control
291.93
282.56
258
277.50
17.52
1.73
10.12

Neg Control
21.27
22.13
20.92
21.44
0.62
1.73
0.36

IFNg vs 1.08mM C
t-Test: Paried Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

Variable 1
277.4966667
307.0392333
3
0.918267065

AS
46.22
42.07
45.33
44.54
2.18
1.73
1.26

1.08mM
Caged AS
109.28
107.36
120.43
112.36
7.06
1.73
4.07

1.08mM
Cage
Flashed AS
92.47
86.73
72.32
83.84
10.38
1.73
5.99

IFNg vs 4.32mM C
t-Test: Paired Two Sample for Means
Variable 2
112.3566667
49.80563333
3

0
2
11.83650476

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail

0.003531047
2.91998558
0.007062093

t Critical two-tail

4.30265273

Variable 1
277.4966667
307.0392333
3

4.32mM
Caged AS
290.25
299.19
227.26
272.23
39.20
1.73
22.63

4.32mM
Cage
Flashed AS
138.64
127.65
204.74
157.01
41.70
1.73
24.07

IFNg vs 6.48mM C
t-Test: Paired Two Sample for Means
Variable 2
272.2333333
1536.931433
3

Variable 1
277.4966667
307.0392333
3

0
2
0.381638367

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail

0.369730481
2.91998558
0.739460961

P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail

0.122953493
2.91998558
0.245906987

t Critical two-tail

4.30265273

t Critical two-tail

4.30265273

0.926824371
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6.48mM
Caged AS
241.39
290.05
203
244.81
43.63
1.73
25.19

0.650714671
0
2
1.623783674

Variable 2
244.8133333
1903.215033
3

1.08 CvsCF
t-Test: Paired Two Sample for Means

Mean
Variance
Observations

Variable 1
112.3566667
49.80563333
3
0.914485578

4.32 CvsCF
t-Test: Paired Two Sample for Means
Variable
2
83.84
107.7697
3

Pearson Correlation
Hypothesized Mean
Difference
0
df
2
t Stat
2.892586662
P(T<=t) one-tail
0.050811501 *
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.101623002
t Critical two-tail
4.30265273
AS vs 1.08mM CF
t-Test: Paired Two Sample for Means
Variable
Variable 1
2
Mean
44.54
83.84
Variance
4.7737 107.7697
Observations
3
3
Pearson Correlation 0.038372318
Hypothesized Mean
Difference
0
df
2
t Stat
6.367372706
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

0.011894166
2.91998558
0.023788332
4.30265273

‡

Mean
Variance
Observations

6.48 CvsCF
t-Test: Paired Two Sample for Means

Variable 1
272.2333333
1536.931433
3
0.999839912

Variable 2
157.01
1738.8097
3

Variable 1
44.54
4.7737
3

Variable 2
157.01
1738.8097
3

Pearson Correlation
Hypothesized Mean
Difference
0
df
2
t Stat
2.466920312
P(T<=t) one-tail
0.066223095
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.132446191
t Critical two-tail
4.30265273
AS vs 4.32mM CF
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean
Difference
df

0
2
4.775205559
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Variable 1
244.8133333
1903.215033
3

Variable 2
213.4533333
1045.726633
3

Pearson Correlation 0.963144985
Hypothesized Mean
Difference
0
df
2
t Stat
3.570639422
P(T<=t) one-tail
0.035133925 *
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.070267851
t Critical two-tail
4.30265273
AS vs 6.48mM CF
t-Test: Paired Two Sample for Means

0.435553598

0.02058284
2.91998558
0.04116568
4.30265273

Mean
Variance
Observations

‡

Variable 1
44.54
4.7737
3
0.595399559

t Stat

0
2
8.685532812

P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

0.006498975
2.91998558
0.01299795
4.30265273

Variable 2
213.4533333
1045.726633
3

‡

Table 2.2:
IFNγ
Stimulated
Control
12.18
8.19
8.19
9.52
2.30
1.73
1.33

AS

average
stdev
sqrt n=3
std. error

78
73
83
78.00
5.00
1.73
2.89

1.08mM CvsCF
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1
66
4
3
0.618589574

1.08 C/F AS
75
78
83
78.67
4.04
1.73
2.33

4.32uM CAS
24
24
27
25.00
1.73
1.73
1.00

4.32mM CvsCF
t-Test: Paired Two Sample for Means
Variable 2
78.66666667
16.33333333
3

0
2
-3.98348238
0.028812967
2.91998558
0.057625934
4.30265273

1.08mM CAS
66
68
64
66.00
2.00
1.73
1.15

*

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1
25
3
3
0.989158483
0
2
4.597372226
0.022099905
2.91998558
0.04419981
4.30265273
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4.32 C/F AS
61
64
45
56.67
10.21
1.73
5.90

6.48uM CAS
29
37
10
25.33
13.87
1.73
8.01

6.48 C/F AS
42
32
21
31.67
10.50
1.73
6.06

6.48mM CvsCF
t-Test: Paired Two Sample for Means
Variable 2
56.66666667
104.3333333
3

*

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1
25.33333333
192.3333333
3
0.704772278
0
2
1.111890898
0.190964977
2.91998558
0.381929954
4.30265273

Variable 2
31.66666667
110.3333333
3

AS vs 1.08mM CF
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

Variable 1
78
25
3

Variable 2
78.66666667
16.33333333
3

0.618589574
0
2
0.285714286

Variable 1
66
4
3
0
0
2
32.06693549
0.000485537
2.91998558
0.000971074
4.30265273

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

P(T<=t) one-tail
0.400985246
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.801970491
t Critical two-tail
4.30265273
IFNg stimulated vs 1.08mM C
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

AS vs 4.32mM CF
t-Test: Paired Two Sample for Means

Variable 2
9.52
5.3067
3

Variable 1
56.66666667
104.3333333
3

Variable 2
78
25
3

-0.93006235
0
2
2.467018702

Variable 1
25
3
3
-0.5
0
2
7.646052837
0.008339182
2.91998558
0.016678364
4.30265273
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Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat

P(T<=t) one-tail
0.066218816
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.132437632
t Critical two-tail
4.30265273
IFNg stimulated vs 4.32mM C
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

AS vs 6.48mM CF
t-Test: Paired Two Sample for Means

Variable 2
9.52
5.3067
3

Variable 1
31.66666667
110.3333333
3
0.523611673

Variable 2
78
25
3

0
2
5.816968957

P(T<=t) one-tail
0.014152298 ‡
t Critical one-tail
2.91998558
P(T<=t) two-tail
0.028304597
t Critical two-tail
4.30265273
IFNg stimulated vs 6.48mM C
t-Test: Paired Two Sample for Means

Mean
Variance
Observations
Pearson
Correlation
Hypothesized
Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1
9.52
5.3067
3
0.228967996
0
2
-2.02463436
0.090096003
2.91998558
0.180192006
4.30265273

Variable 2
25.33333333
192.3333333
3
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